Interventional device developer Boston Scientific of Natick, MA, reports that the Circulatory System Devices Panel has unanimously recommended U. S. Food and Drug Administration approval for the firm’s Taxus Express2 paclitaxel-eluting coronary stent system
The panel provides the FDA with independent professional expertise and technical assistance on the development, safety and efficacy, and regulation of medical devices. A final decision on approval will be made by the FDA, said Boston Scientific.
By AuntMinnie.com staff writersNovember 21, 2003
Related Reading
Biophan joins forces with Boston Scientific, November 5, 2003
Boston Scientific adds to Rubicon investment, October 30, 2003
Q3 gains reported at Boston Scientific, October 22, 2003
FDA sets date to review Boston Scientific stent, September 16, 2003
Boston Scientific releases Taxus clinical results, September 16, 2003
Copyright © 2003 AuntMinnie.com
